

Updated: 04/2019 PARP Approved: 04/2019

Prior Authorization Criteria

Synvisc and Synvisc One (intra-articular hyaluronan injection)

All requests for **Synvisc and Synvisc One** (**intra-articular hyaluronan injection**) require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Coverage may be provided with a <u>diagnosis</u> of osteoarthritis of the knee and the following criteria is met:

- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- Documentation the member is experiencing knee pain that interferes with functional activities related to daily living
- The member must be 18 years and older
- Documentation of which knee(s) is/are being treated
- Must provide documentation showing the member has tried and failed or had an
 intolerance or contraindication to all of the following conservative therapies. All must
 have been attempted and did not result in functional improvement (inadequate response)
 after at least 3 months:
 - · Physical therapy or a physician directed exercise program.
 - Analgesics (acetaminophen) or NSAIDs.
 - Intra-articular corticosteroid injection
- **Initial Duration of Approval:** 1 month
- · Reauthorization criteria
 - Coverage is provided for the other knee if the member has documented improvement in pain and functional capacity of the knee joint with the previous series of injections
 - Coverage is provided for the same knee or both knees if the member had significant improvement in pain and functional capacity of the knee joint with the previous series of injections, and the member's previous treatment was more than 6 months ago.
 - o If the member's previous treatment wasn't more than six months ago, they must be a poor candidate for knee arthroplasty or other therapy due to age, physical or mental impairment.
- **Reauthorization Duration of approval:** 1 month

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.



Updated: 04/2019 PARP Approved: 04/2019

SYNVISC/SYNVISC ONE (INTRA-ARTICULAR HYALURONAN INJECTION) PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Gateway HealthSM Pharmacy Services. **FAX:** (888) 245-2049

If needed, you may call to speak to a Pharmacy Services Representative. **PHONE**: (800) 392-1147 Monday through Friday 8:30am to 5:00pm

1 HO11E. (60	30) 372 1147 Wolld			in to 5.00pm		
	PROVIDER	INFORMAT	ION			
Requesting Provider:			NPI:			
Provider Specialty:			Office Contact:			
Office Address:			Office Phone:			
			Office Fax:			
	MEMBER I	NFORMATI	ION			
Member Name:		DOB:				
Gateway ID:		Member weight:pounds or				
•			kg	•		
	REQUESTED DE	RUG INFORI	MATION			
Medication:		Strength:				
Frequency:			Duration:			
	ing requested medication? Date Medication Initiated:					
Yes No	8 1					
Is this medication being used	for a chronic or long-t	erm condition	for which the	e medication may be		
necessary for the life of the pa		No				
, and the second		Information				
This medication will be billed						
	medically (if me		provide a			
JCODE:		The second of th	P			
Place of Service: Hospita	l Provider's office	ce Memb	er's home	Other		
		vice Informa				
Name:	1 lace of Ser		PI:			
Address:				Phone:		
Tiddless.		11	ione.			
MI	EDICAL HISTORY	Complete for	r ALL reque	ete)		
MEDICAL HISTORY (Complete for ALL requests) Diagnosis: Osteoarthritis of the knee Other:						
If Osteoarthritis of the knee, which knee is affected? Right Both						
ii Osteoarumus or the knee, v	which kiec is affected.	. Kight				
Does the osteoarthritis interfe	ere with activities of da	ily living?	Ves DNo			
Does the osteoarthins interie	Te with activities of da	my nving.		'		
Has the member failed to resp	ond to physical therap	y or a physici	ian directed ex	vercise program? Yes		
Has the marsh - F-11-14	and onland ! !		to imtuot! - 1	on atomaid inication -9 TX		
	ond or had an madequ	iate response	to intraarticul	ar steroid injections? \(\subseteq \text{Yes} \)		
☐ No						
	CHIDDENIE - B					
3.6 11 11 27	CURRENT or PI					
Medication Name	Strength/	Dates of		Status (Discontinued &		
	Frequency	Therap	ру	Why/Current)		
	i	1	1			



Updated: 04/2019 PARP Approved: 04/2019

REAUTHORIZATION					
The member had significant improvement in pain and functional capacity of the knee joint with					
previous injections? Yes No					
Is the member a poor candidate for knee arthroplasty or other therapy due to age, physical, or					
mental impairment? Yes No					
SUPPORTING INFORMATION or CLINICAL RATIONALE					
Prescribing Provider Signature	Date				